Showing 891-900 of 1365 results for "".
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- La Roche-Posay Gives Back: Brand Supports USC's Skin of Color and Pigmentary Disorders Research Fellowshiphttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-supports-uscs-skin-of-color-and-pigmentary-disorders-research-fellowship/2461558/La Roche-Posay is supporting the Skin of Color and Pigmentary Disorders Research Fellowship at the Keck School of Medicine of University of Southern California (USC). The fellowship allows students, between their third and fourth years of medical school, the opportunity to con
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Takeda Completes Acquisition of Nimbus’ TYK2 Subsidiaryhttps://practicaldermatology.com/news/takeda-completes-acquisition-of-nimbus-tyk2-subsidiary/2461552/Takeda has expanded its psoriasis treatment portfolio after completing its acquisition of Nimbus Lakshmi from Nimbus Therapeutics in a deal worth up to $6 billion. Under the agreement, which was announced on December 13, 2022, Takeda will acquire TAK-279, formerly known at Nim
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Sun Pharma to Acquire Concert Pharmaceuticals, Maker of Alopecia Areata Treatment Candidatehttps://practicaldermatology.com/news/sun-pharma-to-acquire-concert-pharmaceuticals-maker-of-alopecia-areata-treatment-candidate/2461519/Sun Pharmaceutical Industries announced it has acquired Concert Pharmaceuticals for about $576 million in equity value, according to a company news release. Concert’s lead product candidate is deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia a
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Study Reveals Novel Insights on Melanin Formationhttps://practicaldermatology.com/news/study-reveals-novel-insights-on-melanin-formation/2461491/“Nrf3” regulates the process of melanin production in mouse and human cells, a new study shows. NF-E2-related factor 3 or “Nrf3,” a known transcription factor, or protein involved in the pro
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as